MedPath

SHANGHAI MABGEEK BIOTECH.CO.,LTD.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

10

Active:4
Completed:0

Trial Phases

4 Phases

Phase 1:3
Phase 2:2
Phase 3:3
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (30.0%)
Phase 3
3 (30.0%)
Not Applicable
2 (20.0%)
Phase 2
2 (20.0%)

Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

Not Applicable
Active, not recruiting
Conditions
Bronchial Asthma
Interventions
Drug: MG-ZG122 Humanized Monoclonal Antibody Injection
Other: Placebo
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
Shanghai Mabgeek Biotech.Co.Ltd
Target Recruit Count
160
Registration Number
NCT07054034
Locations
🇨🇳

China-Japan Friendship Hospital, Beijing, China, Beijing, Beijing, China

Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis

Phase 2
Recruiting
Conditions
Seasonal Allergic Rhinitis
Interventions
Biological: MG-K10 Humanized Monoclonal Antibody Injection
Biological: Placebo
First Posted Date
2025-02-26
Last Posted Date
2025-04-18
Lead Sponsor
Shanghai Mabgeek Biotech.Co.Ltd
Target Recruit Count
160
Registration Number
NCT06846385
Locations
🇨🇳

Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China

Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma

Phase 3
Recruiting
Conditions
Asthma
Interventions
Drug: MG-K10/Placebo
First Posted Date
2025-02-20
Last Posted Date
2025-04-17
Lead Sponsor
Shanghai Mabgeek Biotech.Co.Ltd
Target Recruit Count
504
Registration Number
NCT06837922
Locations
🇨🇳

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis

Phase 3
Recruiting
Conditions
Prurigo Nodularis
Interventions
Drug: Placebo
First Posted Date
2025-01-16
Last Posted Date
2025-04-18
Lead Sponsor
Shanghai Mabgeek Biotech.Co.Ltd
Target Recruit Count
160
Registration Number
NCT06779136
Locations
🇨🇳

Peking University People's Hospital, Beijing,, Beijing, bejing, China

IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients

Phase 1
Recruiting
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2025-01-09
Last Posted Date
2025-01-09
Lead Sponsor
Shanghai Mabgeek Biotech.Co.Ltd
Target Recruit Count
24
Registration Number
NCT06765005
Locations
🇨🇳

Hangzhou First People's Hospital;, Hangzhou, Zhejiang, China

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath